Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Imbruvica
Active substance
Ibrutinib
Therapeutic area (MeSH)
  • Lymphoma, Mantle-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
Procedure number
EMEA/H/C/003791/II/0075
Regulatory outcome
Variation
DHPC type
Post-authorisation measure
Human ATC code
L01EL01
Dissemination date
03/11/2022

Related content

How useful was this page?

Add your rating